KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Share-based Compensation (2016 - 2025)

Travere Therapeutics' Share-based Compensation history spans 13 years, with the latest figure at $11.5 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 24.42% year-over-year to $11.5 million; the TTM value through Dec 2025 reached $44.9 million, up 21.55%, while the annual FY2025 figure was $44.9 million, 21.55% up from the prior year.
  • Share-based Compensation reached $11.5 million in Q4 2025 per TVTX's latest filing, up from $11.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $13.5 million in Q1 2023 to a low of $7.0 million in Q3 2021.
  • Average Share-based Compensation over 5 years is $9.7 million, with a median of $9.5 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: soared 73.2% in 2022, then fell 29.14% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $7.4 million in 2021, then increased by 26.04% to $9.3 million in 2022, then dropped by 12.4% to $8.1 million in 2023, then rose by 13.14% to $9.2 million in 2024, then grew by 24.42% to $11.5 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Share-based Compensation are $11.5 million (Q4 2025), $11.3 million (Q3 2025), and $10.6 million (Q2 2025).